BIO-PATH HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $2.80K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2024 Ended Dec 31, 2024 | Mar 28, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 15, 2024 | Before market open | – | $-0.70 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 15, 2024 | Before market open | – | $-1.16 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | $-4.88 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 8, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 15, 2023 | Before market open | – | $-0.32 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 15, 2023 | Before market open | – | $-0.53 | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 12, 2023 | Before market open | – | $0.66 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 31, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 15, 2022 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 16, 2022 | Before market open | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 17, 2022 | Before market open | – | – | – |
Press releases
Announcements Bio-Path filed with the SEC
Bio-Path Holdings Reports Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings Provides 2025 Clinical and Operational Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.3 to Form 8-K
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Path Holdings Provides Clinical Update and Expansion Plans
Other events · EX-99.1 to Form 8-K
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings Announces $4.0 Million Private
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
Regulation FD disclosure · EX-99.2 to Form 8-K
Bio-Path Holdings Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the- Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Bio-Path Holdings Expands Global Patent Portfolio
Other events · EX-99.1 to Form 8-K
Bio-Path Holdings Provides 2024 Clinical and Operational Update
Regulation FD disclosure · EX-99.1 to Form 8-K
BIO-PATH HOLDINGS REPORTS FULL YEAR 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
Regulation FD disclosure · EX-99.1 to Form 8-K
BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
Regulation FD disclosure · EX-99.1 to Form 8-K
BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
Regulation FD disclosure · EX-99.1 to Form 8-K
BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
BIO-PATH HOLDINGS REPORTS FULL YEAR 2022 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Bio-Path Holdings Provides Clinical and Operational Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
Regulation FD disclosure · EX-99.1 to Form 8-K
BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
our understanding that Bio-Path Holdings, Inc. (the “ Company ”) has engaged ROTH Capital Partners, LLC (“ ROTH ”)
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
to the terms and conditions herein (this “ Agreement ”), Bio-Path Holdings, Inc., a Delaware corporation (the “ Company ”),
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K